Doctor Abandons US Patent Application
By Solomon Times,
Solomon Times
| 04. 11. 2011
The patent application was launched by US based lawyers on behalf of Taiwanese scientist, Dr Ko Ying-Chin.
According to the US Patent Application Information Retrieval system, US based lawyers representing Taiwanese scientist, Dr Ko Ying-Chin, have since filed an express abandonment application on the first of this month for the patent application number.
NIPS says the express abandonment was subsequently processed by the US body on Monday this week and now the status of the US patent application is listed as "expressly abandoned.
Effectively, the patent application is now stopped.
This patent application entitled "Method and Kit for Assessing Risk of Gout and Hyperuricemia," uses samples from 192 Solomon Islanders, collected at the National Referral Hospital and two clinics in Guadalcanal Province during a research trip led by Dr Ko in September 2006.
Dr Ko and his colleagues only abandoned the patent application after NIPS, along with other non-governmental organizations in the Solomon Islands, began to publicly challenge it.
The basis of this challenge was Dr Ko's failure to obtain proper informed consent from the blood donors for such commercialization.
Related Articles
By Gemma Conroy, Nature | 06.27.2024
Image by Robina Weermeijer from Unsplash
A molecular-editing tool that’s small enough to be delivered to the brain shuts down the production of proteins that cause prion diseases, a rare but deadly group of neurodegenerative disorders.
The system — known...
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...